AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low breast cancer in India Read more
AstraZeneca to invest $2.5 bn in new R&D centre, biotech agreements and manufacturing in Beijing Read more